Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
https://www.zacks.com/stock/news/2199515/reasons-to-add-dexcom-dxcm-stock-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199515
Dec 18, 2023 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
0
Abbott (ABT) Gains From Global Expansion Amid Macro Woes
https://www.zacks.com/stock/news/2199328/abbott-abt-gains-from-global-expansion-amid-macro-woes?cid=CS-ZC-FT-analyst_blog|zer_report_update-2199328
Dec 18, 2023 - Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.
0
Thermo Fisher (TMO) to Allocate IFA Testing Kits With New Pact
https://www.zacks.com/stock/news/2199299/thermo-fisher-tmo-to-allocate-ifa-testing-kits-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199299
Dec 18, 2023 - Thermo Fisher (TMO) will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics.
0
Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal
https://www.zacks.com/stock/news/2199231/quest-diagnostics-dgx-haystack-oncology-inks-new-deal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2199231
Dec 18, 2023 - Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.
0
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
https://www.zacks.com/stock/news/2199228/here-s-why-you-should-invest-in-idexx-idxx-stock-right-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199228
Dec 18, 2023 - Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.
0
Here's Why You Should Retain Hologic (HOLX) Stock for Now
https://www.zacks.com/stock/news/2199227/here-s-why-you-should-retain-hologic-holx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199227
Dec 18, 2023 - Investors are optimistic about Hologic (HOLX), which is led by growth with recovery in procedural volumes and acceleration from new business lines.
0
Here's Why You Should Retain Globus Medical (GMED) Stock Now
https://www.zacks.com/stock/news/2198889/here-s-why-you-should-retain-globus-medical-gmed-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198889
Dec 15, 2023 - Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.
0
Neogen (NEOG) to Advance Feline DNA Testing With New Pact
https://www.zacks.com/stock/news/2198888/neogen-neog-to-advance-feline-dna-testing-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2198888
Dec 15, 2023 - Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.
0
Here's Why You Should Retain Catalent (CTLT) Stock for Now
https://www.zacks.com/stock/news/2198761/here-s-why-you-should-retain-catalent-ctlt-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2198761
Dec 15, 2023 - Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.
0
Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger
https://www.zacks.com/stock/news/2198721/align-s-algn-new-launches-aid-macroeconomic-woes-linger?cid=CS-ZC-FT-analyst_blog|zer_report_update-2198721
Dec 15, 2023 - Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.
0